R
Ruth L. Katz
Researcher at University of Texas MD Anderson Cancer Center
Publications - 185
Citations - 11061
Ruth L. Katz is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Fine-needle aspiration & Cancer. The author has an hindex of 48, co-authored 182 publications receiving 10554 citations. Previous affiliations of Ruth L. Katz include University of Texas System & University of Texas at Austin.
Papers
More filters
Journal Article
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
K. Kian Ang,Brian A. Berkey,Xiaoyu Tu,Hua Zhong Zhang,Ruth L. Katz,Elizabeth H. Hammond,Karen K. Fu,Luka Milas +7 more
TL;DR: This correlative study in a large series of patients revealed that EGFR expression, which varied considerably among HNSCCs, was a strong independent prognostic indicator for OS and DFS and a robust predictor for LR relapse but not for distant metastasis.
Journal ArticleDOI
Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.
Martin Korbling,Ruth L. Katz,Abha Khanna,Arnout C.C. Ruifrok,Gabriela Rondon,Maher Albitar,Richard E. Champlin,Zeev Estrov +7 more
TL;DR: All six recipients of sex-mismatched transplants showed evidence of complete hematopoietic donor chimerism and the presence of donor cells in the biopsy specimens did not seem to depend on the intensity of tissue damage induced by graft-versus-host disease.
Journal ArticleDOI
Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.
Feng Jiang,Qi Qiu,Abha Khanna,Nevins W. Todd,Janaki Deepak,Lingxiao Xing,Huijun Wang,Zhenqiu Liu,Yun Su,Sanford A. Stass,Ruth L. Katz +10 more
TL;DR: Immunohistochemical analysis of 303 clinical specimens from three independent cohorts of lung cancer patients and controls show that expression of ALDH1 is positively correlated with the stage and grade of lung tumors and related to a poor prognosis for the patients with early-stage lung cancer.
Journal ArticleDOI
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
Jorge E. Romaguera,Luis Fayad,Maria A Rodriguez,Kristine Broglio,Frederick B. Hagemeister,Barbara Pro,Peter McLaughlin,Anas Younes,Felipe Samaniego,Andre Goy,Andreas H. Sarris,Nam H. Dang,Michael Wang,Virginia Beasley,L. Jeffrey Medeiros,Ruth L. Katz,Harish Gagneja,Barry I. Samuels,Terry L. Smith,Fernando Cabanillas +19 more
TL;DR: Rituximab plus hyper-CVAD alternating with rituxIMab plus high-dose methotrexate and cytarabine is effective in untreated aggressive MCL and toxicity is significant but expected.
Journal ArticleDOI
Plasma microRNAs as potential biomarkers for non-small-cell lung cancer
Jun Shen,Nevins W. Todd,Howard Zhang,Lei Yu,Xing Lingxiao,Xing Lingxiao,Yuping Mei,Maria A. Guarnera,Jipei Liao,Amy Chou,Changwan Larry Lu,Zhengran Jiang,Hong-Bin Fang,Ruth L. Katz,Feng Jiang +14 more
TL;DR: Altered expressions of the miRNAs in plasma would provide potential blood-based biomarkers for NSCLC.